CD40 and B-cell chronic lymphocytic leukemia: These data indicate no direct effects of ibrutinib on CD40-mediated venetoclax resistance, suggesting that the effect of in vivo ibrutinib treatment on CD40 signaling in CLL cells happens indirectly.